The merged pharmaceutical company is now one of the top 10 drugmakers in the world with about $31 billion in revenue. The takeover also strengthens Takeda’s global pipeline for rare disease drugs.
The deal, which is around 46 percent cash and 54 percent stock, also makes the drugmaker one of the most indebted.
Read more about the deal here.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
